Due to increasing rates of CRC in younger individuals, the NCCN Guidelines for Colorectal Cancer Screening support CRC screening in average-risk individuals younger than age 50. Based on the available data and emerging evidence, methods to further enhance access to screening in African American and other minority populations should be endorsed.

The treatment of colorectal cancer continues to evolve and clinician would benefit from education on timely topics.

This activity will address the increasing use of biomarker testing in the management of patients with colorectal cancer, the factors affecting the selection of the appropriate tests, challenges of interpreting test results and communicating the results to patients, and new developments in biomarker testing.

Education is needed to help guide clinicians on appropriate biomarker testing for patients with mCRC and how the results of these tests can aid in treatment decision-making in this rapidly evolving landscape. Optimal treatment strategies can maximize benefits while minimizing harms, giving patients with mCRC the best quality and quantity of life possible.

Trimodal therapy approaches for localized rectal cancer continue to evolve as new data helps define how to best improve outcomes while reducing adverse effects, with total neoadjuvant therapy (TNT) among the approaches of recent interest.  Additionally, new therapies have substantially expanded the treatment options for mCRC in recent years.

As a result of the therapeutic advances and clinical research affecting the management of patients with cancer, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers.

Systemic therapy options in metastatic CRC are continuously evolving and new treatments are becoming available with utilization of various biomarkers. There is a need to review the current landscape of treatment regimens and have an understanding of their place in therapy.

Systemic therapy options in metastatic CRC are continuously evolving and new treatments are becoming available with utilization of various biomarkers. There is a need to review the current landscape of treatment regimens and have an understanding of their place in therapy.